{
  "patient_id": "SA-P004",
  "documents": [
    {
      "visit_number": 1,
      "date": "2025-06-14",
      "type": "progress_note",
      "text": "--- Visit 1 | Date: 2025-06-14 ---\n\nFollow-up visit #1 for patient SA-P004.\n\nVS: 111/90 | HR 73 | Wt 69.0 kg. Patient slightly pale but hemodynamically stable.\n\nBlood work results:\n  - PSA: 0.71 ng/mL [ref 0.0-4.0]\n  - ALT: 19.41 U/L [ref 7.0-56.0]\n  - AST: 28.15 U/L [ref 10.0-40.0]\n  - Hemoglobin: 13.01 g/dL [ref 12.0-17.5]\n  - WBC: 6.81 10^3/uL [ref 4.5-11.0]\n  - Creatinine: 1.04 mg/dL [ref 0.7-1.3]\n\nPlan: Supportive care as needed. Return for cycle 2 in 3 weeks.\n"
    },
    {
      "visit_number": 2,
      "date": "2025-07-05",
      "type": "progress_note_with_imaging",
      "text": "--- Visit 2 | Date: 2025-07-05 ---\n\nPatient SA-P004 presents for scheduled cycle 2 visit.\n\nOn exam, BP is 126/73, pulse 85, wt 81.3 kg. Patient appears well-nourished and in no acute distress.\n\nNo new adverse events reported since last visit.\n\nLaboratory results:\n  - PSA: 0.54 ng/mL [ref 0.0-4.0]\n  - ALT: 20.75 U/L [ref 7.0-56.0]\n  - AST: 25.38 U/L [ref 10.0-40.0]\n  - Hemoglobin: 12.52 g/dL [ref 12.0-17.5]\n  - WBC: 6.08 10^3/uL [ref 4.5-11.0]\n  - Creatinine: 1.1 mg/dL [ref 0.7-1.3]\n\nImaging assessment: Target lesion has increased by approximately 34.7% from nadir. Progressive disease (PD) per RECIST 1.1.\n\nSerum PSA: 4.77 ng/mL, representing a increase of 34.7% compared to baseline.\n\nPlan: Monitor closely and reassess at next visit. Return for cycle 3 in 3 weeks.\n"
    },
    {
      "visit_number": 3,
      "date": "2025-07-26",
      "type": "progress_note",
      "text": "--- Visit 3 | Date: 2025-07-26 ---\n\nVisit 3 clinical encounter for SA-P004.\n\nOn exam, BP is 142/77, pulse 83, wt 56.0 kg. Patient appears well-appearing, cooperative with exam.\n\nNo new adverse events reported since last visit.\n\nLaboratory results:\n  - PSA: 0.01 ng/mL [ref 0.0-4.0]\n  - ALT: 20.36 U/L [ref 7.0-56.0]\n  - AST: 29.03 U/L [ref 10.0-40.0]\n  - Hemoglobin: 12.25 g/dL [ref 12.0-17.5]\n  - WBC: 5.89 10^3/uL [ref 4.5-11.0]\n  - Creatinine: 1.07 mg/dL [ref 0.7-1.3]\n\nContinue study protocol. Monitor labs. Return visit 4 scheduled in 3 weeks.\n"
    },
    {
      "visit_number": 4,
      "date": "2025-08-16",
      "type": "progress_note_with_imaging",
      "text": "--- Visit 4 | Date: 2025-08-16 ---\n\nSA-P004 \u2014 Cycle 4, Day 1 visit.\n\nVS: 122/73 | HR 73 | Wt 82.5 kg. Patient comfortable, no distress noted.\n\nNo new adverse events reported since last visit.\n\nLabs drawn today:\n  - PSA: 0.01 ng/mL [ref 0.0-4.0]\n  - ALT: 23.76 U/L [ref 7.0-56.0]\n  - AST: 28.0 U/L [ref 10.0-40.0]\n  - Hemoglobin: 12.49 g/dL [ref 12.0-17.5]\n  - WBC: 5.99 10^3/uL [ref 4.5-11.0]\n  - Creatinine: 1.1 mg/dL [ref 0.7-1.3]\n\nRestaging CT shows stable disease. Target lesions within +/-15% of prior measurements. No new lesions. RECIST: SD.\n\nPSA now 3.9 ng/mL \u2014 increase 10.2% from initial value.\n\nContinue study protocol. Monitor labs. Return visit 5 scheduled in 3 weeks.\n"
    },
    {
      "visit_number": 5,
      "date": "2025-09-06",
      "type": "progress_note",
      "text": "--- Visit 5 | Date: 2025-09-06 ---\n\nVisit 5 clinical encounter for SA-P004.\n\nOn exam, BP is 119/92, pulse 66, wt 57.1 kg. Patient appears mildly fatigued but alert and oriented.\n\nNeuropathic symptoms noted: mild (Grade 1). Patient describes onset around day 99. Currently ongoing. No dose modification required.\n\nLabs drawn today:\n  - PSA: 0.01 ng/mL [ref 0.0-4.0]\n  - ALT: 25.84 U/L [ref 7.0-56.0]\n  - AST: 29.55 U/L [ref 10.0-40.0]\n  - Hemoglobin: 11.64 g/dL [ref 12.0-17.5] (LOW)\n  - WBC: 5.51 10^3/uL [ref 4.5-11.0]\n  - Creatinine: 1.08 mg/dL [ref 0.7-1.3]\n\nPlan: Continue therapy per protocol with supportive medications. Return for cycle 6 in 3 weeks.\n"
    },
    {
      "visit_number": 6,
      "date": "2025-09-27",
      "type": "progress_note_with_imaging",
      "text": "--- Visit 6 | Date: 2025-09-27 ---\n\nVisit 6 clinical encounter for SA-P004.\n\nVital signs obtained: blood pressure 160/86, heart rate 73, weight 93.8 kg.\n\nLab panel results from today's draw:\n  - PSA: 0.01 ng/mL [ref 0.0-4.0]\n  - ALT: 22.76 U/L [ref 7.0-56.0]\n  - AST: 29.63 U/L [ref 10.0-40.0]\n  - Hemoglobin: 12.01 g/dL [ref 12.0-17.5]\n  - WBC: 5.18 10^3/uL [ref 4.5-11.0]\n  - Creatinine: 1.17 mg/dL [ref 0.7-1.3]\n\nImaging reveals meaningful tumor shrinkage consistent with partial response (PR). Target lesion regression of ~46.0%.\n\nPSA now 1.91 ng/mL \u2014 decrease 46.0% from initial value.\n\nContinue study protocol. Monitor labs. Return visit 7 scheduled in 3 weeks.\n"
    },
    {
      "visit_number": 7,
      "date": "2025-10-18",
      "type": "progress_note",
      "text": "--- Visit 7 | Date: 2025-10-18 ---\n\nPatient SA-P004 presents for scheduled cycle 7 visit.\n\nVital signs obtained: blood pressure 150/85, heart rate 64, weight 95.4 kg.\n\nBlood work results:\n  - PSA: 0.01 ng/mL [ref 0.0-4.0]\n  - ALT: 27.08 U/L [ref 7.0-56.0]\n  - AST: 28.17 U/L [ref 10.0-40.0]\n  - Hemoglobin: 11.56 g/dL [ref 12.0-17.5] (LOW)\n  - WBC: 5.68 10^3/uL [ref 4.5-11.0]\n  - Creatinine: 1.13 mg/dL [ref 0.7-1.3]\n\nPlan: Continue current regimen. Follow up in 3 weeks.\n"
    },
    {
      "visit_number": 8,
      "date": "2025-11-08",
      "type": "missed_visit_note",
      "text": "--- Visit 8 | Date: 2025-11-08 ---\n\nNo-show for cycle 8 visit. Staff attempted follow-up: patient's family member confirmed patient was unwell.\n\nInvestigator decision to discontinue patient from study in best interest of patient care.\n"
    }
  ]
}